The drugmaker should significantly mitigate its most important risk as it develops new products.

Amgen, Gilead and Vertex all show up in the same note, but the bank isn't treating them equally.

Omeros stock rocketed to a five-year high Thursday on blowout second-quarter results for its new treatment for transplant ...

New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t ...

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce ...

UC Santa Cruz deepens industry engagement to underscore its vital role in contributing basic research and tomorrow’s talent, convening its first international RNA biotech conference on August 18 ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real question is ...

This is not possible without a steadfast commitment from our partners in the federal government and private industry. It’s important to acknowledge and evaluate the current constraints. On the ...

Georgia Witchel's Mantis Biotech makes Parva, consumer software that reads how a person types and clicks to flag cognitive change relative to their own baseline, not a population average, largely ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...